Glucotrack, INC 8-K filings

Glucotrack, Inc. announced the successful repurchase of over 90% of its outstanding Series A Warrants, aiming to strengthen its capital structure and reduce potential share dilution.

Glucotrack, Inc. announced positive final results from its first-in-human clinical study for its implantable Continuous Blood Glucose Monitor, demonstrating strong accuracy with a 7.7% MARD and excellent safety.

Glucotrack, Inc. has completed a 1-for-60 reverse stock split, effective June 13, 2025, significantly reducing its outstanding shares and adjusting per-share financial metrics.

Glucotrack, Inc. has announced a 1-for-60 reverse stock split, effective June 16, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement and attracting institutional investors.

Glucotrack, Inc. announced it will present safety and performance data from its first-in-human trial of its implantable continuous blood glucose monitoring system at the American Diabetes Association's 85th Scientific Sessions.

Glucotrack, Inc. announced that its stockholders approved a reverse stock split, an increase in shares for its equity incentive plan, and the election of directors at its 2025 annual meeting.

GlucoTrack, Inc. forms a Patient Advisory Board to incorporate patient insights into the development of its long-term implantable Continuous Blood Glucose Monitor (CBGM).

Glucotrack announces its Q1 2025 financial results, highlighting progress in its CBGM development and upcoming clinical trials.

Glucotrack, Inc. has received ethical approval for a long-term clinical study of its continuous blood glucose monitor (CBGM) in participants with type 1 and type 2 diabetes.

GlucoTrack, Inc. issued an investor presentation on April 29, 2025.

Glucotrack, Inc. will participate in the FORGETDIABETES initiative, a European research program focused on developing a bionic pancreas for automated insulin delivery.

GlucoTrack, Inc. received a delisting notice from Nasdaq due to its common stock price falling below the required $1.00 per share minimum.

GlucoTrack, Inc. announces a strategic agreement with OneTwo Analytics AB to leverage AI-driven analytics for its Continuous Blood Glucose Monitor (CBGM) clinical study data.

Glucotrack, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, highlighting its transition to a clinical-stage company and advancements in its continuous blood glucose monitoring (CBGM) technology.

Glucotrack, Inc. announces the presentation of safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes.

GlucoTrack, Inc. announces the conversion of debt and warrants into common stock, issuing shares to note investors and warrant holders.

Glucotrack, Inc. announces the appointment of Dr. Guillermo Umpierrez to its Medical Advisory Board as the company advances its long-term implantable blood glucose monitoring technology.

GlucoTrack, Inc. distributed a slide presentation as a shareholder update on February 14, 2025.

Glucotrack, Inc. has announced the pricing of a $3.0 million public offering of common stock at $1.15 per share.

GlucoTrack, Inc. announces a 1-for-20 reverse stock split and the successful completion of its first in-human clinical study for its continuous blood glucose monitor (CBGM).

Glucotrack, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective February 4, 2025, to meet Nasdaq's minimum bid price requirement.

Glucotrack, Inc. has appointed Peter C. Wulff as its new Chief Financial Officer, effective immediately, following the resignation of James Cardwell.

Glucotrack, Inc. has announced it received ISO 13485:2016 certification from the British Standards Institute, demonstrating its commitment to quality in the design and manufacturing of its continuous blood glucose monitor.

GlucoTrack files an amendment to its previous 8-K report to correct a scrivener's error regarding the number of shares issuable upon exchange of Series B Warrants.

GlucoTrack, Inc. reports the issuance of 134,785,015 shares of common stock following the exchange of Series B Warrants.

Glucotrack, Inc. will present an update on its continuous blood glucose monitor at the TechBio Showcase 2025.

Glucotrack Inc. stockholders approved an increase in authorized shares and a reverse stock split at a special meeting on January 3, 2025.

GlucoTrack, Inc. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, triggering a 180-day compliance period.

GlucoTrack, Inc. has entered into an agreement to sell up to $8.23 million of its common stock through an at-the-market offering program.

Glucotrack has initiated patient enrollment for a short-term human clinical study of its continuous blood glucose monitor, which measures glucose directly from blood.